Interview with Diatheris Co-founders, Giorgio Ramadori (CEO) & Roberto Coppari (CSO)

Please tell us about your journey that led you to become an entrepreneur?

For more than a decade, our dedicated efforts have focused on unraveling mechanisms that sustain life in the absence of insulin. From the outset, we recognized the potential for significant translational findings, especially in the realm of diabetes. Through the use of distinctive discovery models, we pinpointed S100A9 as a factor capable of extending the lifespan of insulin-deficient mice while simultaneously improving glycemic and ketonemic profiles. Recognizing the translational implications, particularly the prospect of using S100A9 in conjunction with reduced insulin doses for more effective type 1 diabetes management, we swiftly grasped the need to transform this discovery into a viable medical solution. This realization prompted us to establish commercial value, beginning with patent protection and progressing to a robust development plan. Consequently, we acknowledged the imperative to spin off the project from the academic setting and assemble a team endowed with diverse expertise and skills. This marked the inception of our journey with Diatheris.

?

Can you share with us what your company does and what is your unique selling point?

At Diatheris, we're developing a groundbreaking therapeutic solution aimed at revolutionizing the management of type 1 diabetes. Our innovative approach involves the subcutaneous injection of an endogenous protein, S100A9, offering a safer and more effective means of blood sugar control. This method not only reduces the therapeutic requirement for insulin but also mitigates the risks associated with hypoglycemia and diabetic ketoacidosis—persistent challenges in current type 1 diabetes treatments. Ultimately, our goal is to develop a therapeutic solution that elevates both the efficacy of therapy and the overall quality of life for individuals with type 1 diabetes.

?

What are some of the milestones that you envision for your company this year?

This year, we anticipate the completion of preclinical studies, positioning us to initiate the clinical trial application process in 2025.

Can you share a message for other entrepreneurs that would like to do the same as you?

Ignite your passion, confront challenges with unwavering determination, maintain focus, and assemble a standout team. Success flourishes through innovation, collaboration, and a sprinkle of luck for those bold enough to seize it.